过敏性支气管肺曲菌病
奥马佐单抗
三级护理
医学
曲菌病
儿科
重症监护医学
免疫学
内科学
免疫球蛋白E
抗体
作者
Mehmet Erdem Cakmak,Nida Öztop,Osman Ozan Yeğit
出处
期刊:Journal of Asthma
[Taylor & Francis]
日期:2024-07-03
卷期号:61 (12): 1663-1671
被引量:1
标识
DOI:10.1080/02770903.2024.2375271
摘要
Introduction Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by a hypersensitivity reaction to antigens of Aspergillus fumigatus.Objective The aim of this study was to evaluate the long-term clinical outcomes of omalizumab use in patients with ABPA.Methods In this retrospective study, 12 patients diagnosed with ABPA and receiving omalizumab for at least 2 years, and 32 patients diagnosed with severe allergic asthma and receiving omalizumab for at least 2 years (control group) were evaluated.Results Evaluation was made of a total of 44 participants, comprising 11 (25%) males and 33 (75%) females, who received omalizumab for at least 2 years with the diagnosis of the control group (n = 32) and ABPA (n = 12). The increase in asthma control test (ACT) score after omalizumab was significant at 12 months and at 24 months in patients with ABPA. After omalizumab, the use of oral corticosteroid (OCS), the annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in patients with ABPA. The increase in forced expiratory volume in 1 s (FEV1) (%) and ACT score after omalizumab were significant at 12 months and at 24 months in the control group. After omalizumab, the use of OCS, annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in the control group.Conclusion Long-term omalizumab use in patients with ABPA seems to be an effective treatment for improving pulmonary function and reducing asthma exacerbations and hospitalizations.
科研通智能强力驱动
Strongly Powered by AbleSci AI